Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Martin Wilson Sells 12,253 Shares

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) General Counsel Martin Wilson sold 12,253 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $3.31, for a total value of $40,557.43. Following the completion of the transaction, the general counsel directly owned 683,376 shares in the company, valued at $2,261,974.56. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Rocket Pharmaceuticals Trading Up 4.2%

RCKT stock traded up $0.14 during trading on Wednesday, reaching $3.45. 2,561,307 shares of the stock traded hands, compared to its average volume of 2,114,616. The firm has a market capitalization of $373.37 million, a PE ratio of -1.53 and a beta of 0.48. The company has a debt-to-equity ratio of 0.06, a current ratio of 7.30 and a quick ratio of 7.30. The business’s 50 day moving average price is $3.50 and its 200-day moving average price is $3.38. Rocket Pharmaceuticals, Inc. has a 52-week low of $2.19 and a 52-week high of $11.09.

Analyst Ratings Changes

A number of analysts recently issued reports on RCKT shares. Morgan Stanley set a $5.00 target price on shares of Rocket Pharmaceuticals in a research report on Thursday, January 8th. Wedbush reiterated an “outperform” rating and set a $16.00 price objective on shares of Rocket Pharmaceuticals in a research note on Friday, November 7th. TD Cowen raised shares of Rocket Pharmaceuticals to a “hold” rating in a research note on Friday, December 19th. JPMorgan Chase & Co. lowered shares of Rocket Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, November 18th. Finally, Bank of America decreased their price target on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, November 18th. Eight investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $14.36.

Institutional Trading of Rocket Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Prudential Financial Inc. purchased a new position in shares of Rocket Pharmaceuticals in the second quarter valued at $25,000. CANADA LIFE ASSURANCE Co lifted its holdings in Rocket Pharmaceuticals by 94.4% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock worth $29,000 after buying an additional 5,926 shares in the last quarter. Corton Capital Inc. acquired a new position in Rocket Pharmaceuticals in the 2nd quarter worth $38,000. Franklin Resources Inc. purchased a new position in Rocket Pharmaceuticals in the 4th quarter valued at about $38,000. Finally, Virtu Financial LLC purchased a new position in Rocket Pharmaceuticals in the 3rd quarter valued at about $40,000. Hedge funds and other institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.